IL292359A - Prostate cancer treatment methods - Google Patents
Prostate cancer treatment methodsInfo
- Publication number
- IL292359A IL292359A IL292359A IL29235922A IL292359A IL 292359 A IL292359 A IL 292359A IL 292359 A IL292359 A IL 292359A IL 29235922 A IL29235922 A IL 29235922A IL 292359 A IL292359 A IL 292359A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- formula
- pct
- day
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924655P | 2019-10-22 | 2019-10-22 | |
| US201962945418P | 2019-12-09 | 2019-12-09 | |
| US202063028843P | 2020-05-22 | 2020-05-22 | |
| US202063032453P | 2020-05-29 | 2020-05-29 | |
| PCT/US2020/056684 WO2021081108A1 (en) | 2019-10-22 | 2020-10-21 | Methods of treating prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292359A true IL292359A (en) | 2022-06-01 |
Family
ID=73449188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292359A IL292359A (en) | 2019-10-22 | 2020-10-21 | Prostate cancer treatment methods |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20210113557A1 (https=) |
| EP (1) | EP4048236A1 (https=) |
| JP (2) | JP7716396B2 (https=) |
| KR (1) | KR20220087482A (https=) |
| CN (1) | CN115135313A (https=) |
| AU (1) | AU2020370150A1 (https=) |
| CA (1) | CA3158411A1 (https=) |
| IL (1) | IL292359A (https=) |
| MX (1) | MX2022004808A (https=) |
| WO (1) | WO2021081108A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| WO2022048605A1 (zh) * | 2020-09-04 | 2022-03-10 | 南昌奥瑞药业有限公司 | 一种杂环化合物、其制备方法、中间体、组合物以及应用 |
| JP2023547084A (ja) * | 2020-10-21 | 2023-11-09 | アルビナス・オペレーションズ・インコーポレイテッド | アンドロゲン受容体タンパク質の標的分解のための化合物および方法 |
| JP2023552818A (ja) * | 2020-12-11 | 2023-12-19 | アルビナス・オペレーションズ・インコーポレイテッド | 前立腺癌を治療する方法 |
| CN113620931B (zh) * | 2021-09-13 | 2023-06-09 | 中国海洋大学 | 一种雄激素受体抑制剂及其用途 |
| US20250248999A1 (en) * | 2022-04-21 | 2025-08-07 | Arvinas Operations, Inc. | Bavdegalutamide and combinations thereof for use in treating prostate cancer |
| WO2024233696A1 (en) * | 2023-05-09 | 2024-11-14 | Arvinas Operations, Inc. | Bavdegalutamide for treating prostate cancer without ar l702h mutation |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US20140255413A1 (en) * | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| US20140287039A1 (en) * | 2013-03-15 | 2014-09-25 | Iceutica Inc. | Abiraterone Acetate Formulation |
| WO2015114314A1 (en) * | 2014-01-28 | 2015-08-06 | Cipla Limited | Pharmaceutical composition comprising abiraterone |
| RU2738833C9 (ru) * | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| WO2016081472A1 (en) * | 2014-11-21 | 2016-05-26 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual formulation of riluzole |
| CN109310664A (zh) * | 2016-06-10 | 2019-02-05 | 田纳西大学研究基金会 | 选择性雄激素受体降解剂(sard)配体和其使用方法 |
| JOP20190067A1 (ar) * | 2016-09-30 | 2019-03-28 | Janssen Pharmaceutica Nv | طُرق تشخيص وعلاج سرطان البروستاتا النقيلي المقاوم للإخصاء والمقاوم أو الحساس لأبيراتيرون أسيتات-الهرمون القشري السكري |
| CN110506039A (zh) * | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
-
2020
- 2020-10-21 KR KR1020227016404A patent/KR20220087482A/ko not_active Ceased
- 2020-10-21 MX MX2022004808A patent/MX2022004808A/es unknown
- 2020-10-21 CA CA3158411A patent/CA3158411A1/en active Pending
- 2020-10-21 CN CN202080080511.2A patent/CN115135313A/zh active Pending
- 2020-10-21 WO PCT/US2020/056684 patent/WO2021081108A1/en not_active Ceased
- 2020-10-21 IL IL292359A patent/IL292359A/en unknown
- 2020-10-21 AU AU2020370150A patent/AU2020370150A1/en active Pending
- 2020-10-21 US US17/075,808 patent/US20210113557A1/en not_active Abandoned
- 2020-10-21 EP EP20807571.3A patent/EP4048236A1/en not_active Withdrawn
- 2020-10-21 JP JP2022523564A patent/JP7716396B2/ja active Active
-
2022
- 2022-12-21 US US18/085,869 patent/US20230128132A1/en not_active Abandoned
-
2025
- 2025-07-18 JP JP2025120941A patent/JP2025157436A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7716396B2 (ja) | 2025-07-31 |
| JP2022553954A (ja) | 2022-12-27 |
| US20230128132A1 (en) | 2023-04-27 |
| CN115135313A (zh) | 2022-09-30 |
| AU2020370150A1 (en) | 2022-05-12 |
| US20210113557A1 (en) | 2021-04-22 |
| JP2025157436A (ja) | 2025-10-15 |
| CA3158411A1 (en) | 2021-04-29 |
| WO2021081108A1 (en) | 2021-04-29 |
| EP4048236A1 (en) | 2022-08-31 |
| KR20220087482A (ko) | 2022-06-24 |
| MX2022004808A (es) | 2022-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292359A (en) | Prostate cancer treatment methods | |
| ES2978534T3 (es) | Análogos de éter de fosfolípidos como vehículos de fármacos contra el cáncer | |
| ES2428291T3 (es) | Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos | |
| US5945412A (en) | Methods and compositions for preventing and treating bone loss | |
| JP6991993B2 (ja) | 痛覚過敏を治療する方法 | |
| US4668684A (en) | Combination of flupirtin and anticholinergic acting spasmolytic | |
| US20250161280A1 (en) | Combination therapy using azabicyclo compound for cancer | |
| CA3214530A1 (en) | Combination therapies using prmt5 inhibitors for the treatment of cancer | |
| ES2736507T3 (es) | 2-Tioxo-imidazolidin-4-onas sustituidas y análogos espiro de las mismas, ingrediente activo contra el cáncer, composición farmacéutica, preparación medicinal, método para tratar cáncer de próstata | |
| RS66424B1 (sr) | Kombinovane terapije | |
| US9358247B2 (en) | Methods and compositions for promoting activity of anti-cancer therapies | |
| US20120264795A1 (en) | Combination therapy with parp inhibitors | |
| TW202010502A (zh) | 包含糖皮質激素受體拮抗劑之固體形式與調配物及其用途 | |
| KR20210066841A (ko) | 신규한 퀴나졸린 egfr 억제제 | |
| ES2762641T3 (es) | Inhibidores de proteína quinasa de 2-aminopiridina sustituida con piridina | |
| SA520412533B1 (ar) | تثبيط قناة الأيون المحتملة للمستقبل العابر a1 | |
| US20100286038A1 (en) | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same | |
| JP2006070032A (ja) | 抗血管形成薬剤組成物 | |
| ES2330324T3 (es) | Derivados del epotilon para el tratamiento del hepatoma y de otros canceres. | |
| CN101485887B (zh) | 5-氟尿嘧啶-sn2-磷脂酰胆碱共聚物及其制备方法和用途 | |
| CA2801448A1 (en) | Cancer treatment with wortmannin analogs | |
| WO2022261643A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
| CN108853008A (zh) | 一种可注射天然产物凝胶的制备方法及其应用 | |
| EP2200584A2 (en) | Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same | |
| US12285412B1 (en) | Organoselenium benzimidazole compounds for treating cancer |